Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000938
Chunk: 50

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 50
---
 quoted on the Principal Market, subject only to customary listing conditions, trading in the Depositary
Shares shall not have been within the last 365 days suspended by the SEC or the Principal Market, and all Depositary Shares representing
Securities to be issued by the Company to the Investor pursuant to this Agreement shall have been approved for listing or quotation, if
applicable, on the Principal Market in accordance with the applicable rules and regulations of the Principal Market, subject only to official
notice of issuance and any standard listing conditions for transactions of this nature;

| -26- |

(d) The
Investor shall have received the opinions of the Company’s United States and United Kingdom legal counsel, each dated as of the
Commencement Date, substantially in the form heretofore agreed by the parties hereto;

(e) The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in above, in which case, the portion of such representations
and warranties so qualified shall be true and correct without further qualification) as of the Execution Date and as of the Commencement
Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and
correct as of such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement
Date. The Investor shall have received a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement
Date, to the foregoing effect in the form attached hereto as Exhibit A;

(f) The
Board of Directors, or a committee thereof, shall have adopted resolutions approving the transactions contemplated hereby, which resolutions
shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date;

(g) As
of the Commencement Date, the Company shall have allotted (i) solely for the purpose of effecting purchases of Purchase Shares hereunder,
up to 350,000,000,000 Ordinary Shares, which represents 35,000,000 Depositary Shares sold at the Floor Price per Depositary Share, and
(ii) solely for the purpose of effecting the issuance of Commitment Shares hereunder, if any, up